# Proven to help health centers serve the complex needs of patients with SUD

Clinical drug monitoring (CDM) and other valuable services from Quest Diagnostics give your community health center (CHC) proven tools to help manage patients prescribed controlled substances, identify potential drug misuse, and screen for infectious disease.









medMATCH® Results



**Toxicologists** 



Infectious Disease Screening

# Why now is a good time to consider CDM

**Driven by the opioid epidemic and the evolving drug misuse crisis,** the need for substance use disorder (SUD) services is growing. CHCs are located in medically underserved rural and urban areas, where the impact of the opioid epidemic has been the most severe.

 $2010 \rightarrow 2016^{1,2}$ 



**143**%

**Increase in patients** receiving SUD services in CHCs

**9** 

**136**%

Increase in full-time CHC staff providing SUD services

With more than **9 out of 10 CHC** patients being low income, and **8 out of 10** uninsured or publicly insured, <sup>1</sup> CHCs are working to break down barriers to care while making SUD services more accessible. **Clinical drug monitoring is a proven way to help you identify drug misuse, mitigate risk, and better serve the complex needs of your most at-risk patients.** 



# How CDM from Quest can help your patients and health center

Quest can help you establish a CDM program to protect your patients and your community from the consequences of unidentified drug misuse and to carry out infectious disease screening to protect against undiagnosed infections such as HIV and hepatitis C.

### What we offer: CDM tools and services

- → Resources to aid you in **creating a CDM protocol**
- → Comprehensive drug screening options to cover prescribed, nonprescribed, and illicit drugs
- → Fast turnaround time and results confirmation, with presumptive and definitive testing
- → **Highly sensitive testing,** featuring low cutoff levels designed to detect drugs at typical dosage levels
- → Exceptional service and efficiency that aligns with your workflow, including seamless connectivity
- → **Dedicated, specialty-focused team** with the resources of a leading national lab

# Clear results with medMATCH® reporting


- → Easy-to-read format that displays and interprets drug test results at a glance
- → Quarterly practice level data and analytics

# Increased vigilance with infectious disease screening

- → Comprehensive test menu from a leader in infectious disease screening
- → Reflex testing options can improve speed-to-treatment
- → Can improve management of patients at high risk, such as those patients using illicit drugs by injection

## Professional support from our team of toxicology specialists

**Experts available** to help answer questions, address your concerns, and consult on results



# Higher-quality care management for your patients with SUD

Let us help you launch a clinical drug monitoring program that serves the needs of your patients with SUD while allowing your health center to safely expand access to SUD services. Ask your Quest representative for details on how to begin.

### References

1. Kaiser Family Foundation (KFF). Community health centers: growing importance in a changing health care system. Sara Rosenbaum, Jennifer Tolbert, Jessica Sharac, Peter Shin, Rachel Gunsalus, and Julia Zur. March 2018. Accessed April 21, 2020. https://www.kff.org/report-section/community-health-centers-growing-importance-in-a-changing-health-care-system-issue-brief. 2. National Association of Community Health Centers (NACHC). Rising to the challenge: community health centers are making substance use disorder treatment more accessible than ever. March 2018. Accessed April 21, 2020. http://www.nachc.org/wp-content/uploads/2018/03/NACHC\_PI\_2018\_WEB\_v1.pdf.
3. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recomm Rep. 2016;65:1–49. 4. Degenhardt L, Peacock A, Colledge S et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192–1207.

### QuestDiagnostics.com

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. ©2020 Quest Diagnostics Incorporated. All rights reserved. SB9556 8/2020



A **robust CDM program** can reduce risks associated with long-term prescription drug therapy<sup>3</sup>

